ZDA
GHDX

Zweig-DiMenna Associates’s Genomic Health, Inc. GHDX Stock Holding History

Zweig-DiMenna Associates’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-93,759
Closed -$3.3M – 295
2015
Q4 		$3.3M Buy
+93,759
New +$2.51M 0.16% 117

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Zweig-DiMenna Associates's GHDX Position: Q1 2016 in Review

Zweig-DiMenna Associates sold out of Genomic Health, Inc. (GHDX) in Q1 2016, closing a stake of 93,759 shares — an estimated $3.3M sold.

Zweig-DiMenna Associates first reported a position in GHDX in Q4 2015 and held it in 1 quarter. The position peaked at $3.3M in Q4 2015. 127 funds tracked by Wall St. Rank hold GHDX as of Q1 2016.

  • Zweig-DiMenna Associates reported no remaining Genomic Health, Inc. position as of Q1 2016 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 93,759 Genomic Health, Inc. shares in Q1 2016, an estimated $3.3M.
  • Zweig-DiMenna Associates first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Genomic Health, Inc. position peaked at $3.3M in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2016.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2016, filed 10 May 2016.